

Nakinadine A, a novel bis-pyridine alkaloid with a β -amino acid moiety from sponge *Amphimedon* sp.

Takaaki Kubota,^a Takami Nishi,^a Eri Fukushi,^b Jun Kawabata,^b
Jane Fromont^c and Jun'ichi Kobayashi^{a,*}

^aGraduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

^bGraduate School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan


^cWestern Australian Museum, Locked Bag 49, Welshpool DC, WA 6986, Australia

Received 24 April 2007; revised 20 May 2007; accepted 22 May 2007

Available online 24 May 2007

Abstract—A novel cytotoxic bis-3-alkylpyridine alkaloid with a β -amino acid moiety, nakinadine A (**1**), has been isolated from an Okinawan marine sponge *Amphimedon* sp., and the structure and stereochemistry were elucidated by spectroscopic data.
© 2007 Elsevier Ltd. All rights reserved.

Marine sponges are a rich source of bioactive secondary metabolites with unprecedented skeletons. A number of 3-alkylpyridine alkaloids have been isolated from marine sponges of several genera.¹ Most of them possess a long aliphatic chain with a various nitrogen-containing terminus,² some of which have dimeric or polymeric structures of 3-alkylpyridine.³ During our continuing search for bioactive substances from marine sponges,⁴ we previously isolated cytotoxic pyridine alkaloids from sponges of the genera *Theonella*,⁵ *Nyphates*,⁶ *Amphimedon*,⁷ and *Cribrochalina*.^{4,8} Here we describe the isolation and structure elucidation of a novel cytotoxic 3-alkylpyridine alkaloid, nakinadine A (**1**),⁹ from a marine sponge *Amphimedon* sp. (SS-1059).



Stereochemistry denotes relative one.

Keywords: Sponge; Alkaloid; Pyridine; β -Amino acid.

* Corresponding author. Tel.: +81 11 706 3239; fax: +81 11 706 4989; e-mail: jkobay@pharm.hokudai.ac.jp

The sponge *Amphimedon* sp. (SS-1059) collected off Nakijin, Okinawa, was extracted with MeOH. EtOAc-soluble materials of the MeOH extract were subjected to a silica gel column (CHCl₃/MeOH), in which a fraction eluted with CHCl₃/MeOH (9:1) was purified by an amino silica gel column (CHCl₃/MeOH) followed by C₁₈ HPLC (MeOH/H₂O) to afford nakinadine A (**1**, 0.001%, wet weight).

Nakinadine A (**1**) was revealed to have the molecular formula, C₄₅H₆₇N₃O₂, by HRESIMS [m/z 682.5311 (M+H)⁺, Δ +0.0 mmu]. Aromatic proton signals [H-2, H-2', H-6, and H-6', δ_{H} 8.44 (4H); H-4 and H-4', δ_{H} 7.49 (2H); H-5 and H-5', δ_{H} 7.19 (2H)] and [H-25 and H-29, δ_{H} 7.32 (2H); H-26 and H-28, δ_{H} 7.20 (2H); H-27, δ_{H} 7.15 (1H)] in the ¹H NMR spectrum and five pairs of sp² carbon signals [C-2 and C-2', δ_{C} 149.6 (2C, d); C-3 and C-3', δ_{C} 136.9 (2C, s); C-4 and C-4', δ_{C} 135.5 (2C, d); C-5 and C-5', δ_{C} 122.9 (2C, d); C-6 and C-6', δ_{C} 146.8 (2C, d)] and four sp² carbon signals [C-24, δ_{C} 135.8 (s); C-25 and C-29, δ_{C} 129.4 (2C, d); C-26 and C-28, δ_{C} 128.2 (2C, d); C-27, δ_{C} 127.0 (d)] in the ¹³C NMR spectrum suggested that **1** possessed two 3-alkylpyridine rings and a phenyl group. ¹³C NMR data disclosed the presence of a carbonyl carbon (δ_{C} 176.0). IR absorptions at 3400–3000, 2900–2600, and 1725 cm⁻¹ indicated the presence of carboxylic acid functionality. Treatment of **1** with TMS-CHN₂ gave the methyl ester of **1** [ESIMS (pos.) m/z 696 (M+H)⁺]. Since the ¹H and ¹³C NMR data of **1** [H-9' and H-10', δ_{H} 5.33 (2H); C-9', δ_{C} 127.4 (d); C-10', δ_{C} 131.1 (d)]




Figure 1. Selected 2D NMR correlations for nakinadine A (**1**).

indicated the presence of a disubstituted double bond, fourteen unsaturation numbers were accounted for.

The gross structure of **1** was elucidated by analyses of 2D NMR data in CD₃OD (Fig. 1). The ¹H–¹H COSY, TOCSY, and HMBC spectra revealed connectivities from two β-substituted pyridine rings to C-8 and C-12'. *Z*-Geometry of an olefin at C-9' was assigned as *Z* from the chemical shifts of allylic carbons [C-8', δ_C 28.4; C-11', δ_C 26.9].¹⁰ The ¹H–¹H COSY and TOCSY spectra of **1** revealed connectivities of C-18 to C-19, and C-21 to C-22 and C-19', and C-18' to C-19'. The ¹H and ¹³C NMR data suggested that C-19 [δ_H 2.75 (1H) and 2.62 (1H); δ_C 44.9 (t)] and C-21 [δ_H 3.19 (1H); δ_C 59.5 (d)] were adjacent to a nitrogen atom. The connectivity of C-19 to C-21 through a nitrogen atom was implied by HMBC cross-peaks for H₂-19 to C-21. HMBC cross-peaks for H-22 to C-23 and C-25, and H-29 to C-24 indicated that a carboxy group and phenyl group were both attached to C-22.

Analysis of the ESIMS/MS spectrum of **1** revealed connectivities from C-8 to C-18 and from C-12' to C-18' (Fig. 2). These fragmentation patterns also supported the proposed structure of nakinadine A (**1**).

The relative stereochemistry of **1** was deduced from NOESY correlations and *J*-values¹¹ as shown in Figure 3. A *gauche* relation for H-21 and H-22 was deduced from the NOESY cross-peak for H-21/H-22 and ³*J*_{H-21/H-22} (2 Hz). The NOESY cross-peaks for H-21/H-25 and H-21/H-26 suggested a *gauche* relation for H-21 and a phenyl group. A large coupling constant (³*J*_{H-22/C-19'} = 8 Hz), which was obtained from HET-





Figure 3. Rotation model for C-21–C-22 of nakinadine A (**1**).



Scheme 1. Plausible biogenetic path of nakinadine A (**1**).

LOC spectrum of **1**, indicated an *anti* relation for H-22 and C-19' (Fig. 3).

Nakinadine A (**1**) is the first bis-3-alkylpyridine alkaloid with a β-amino acid moiety.¹² Biogenetically, nakinadine A (**1**) might be generated from an intermediate **A** and phenylacetic acid through Mannich-type reaction (Scheme 1).¹³ Nakinadine A (**1**) showed cytotoxicity against L1210 murine leukemia (IC₅₀, 1.3 μg/mL) and KB human epidermoid carcinoma cells (IC₅₀, 2.5 μg/mL) in vitro.

Acknowledgments

The authors thank Z. Nagahama and K. Uehara for their help with collection of the sponge, Ms. S. Oka, Center for Instrumental Analysis, Hokkaido University, for measurements of ESIMS. This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.

References and notes

- Blunt, J. W.; Copp, B. R.; Hu, W.-P.; Munro, M. H. G.; Northcote, P. T.; Prinsep, M. R. *Nat. Prod. Rep.* **2007**, *24*, 31–86.




Figure 2. Fragmentation pattern of nakinadine A (**1**) in ESI MS/MS. [parent ion; (a) at *m/z* 682 (M+H)⁺, (b) at *m/z* 546 (M–C₈H₆O₂+H)⁺].

2. (a) Quiñoa, E.; Crews, P. *Tetrahedron Lett.* **1987**, *28*, 2467–2468; (b) Sakemi, S.; Totton, L. E.; Sun, H. H. *J. Nat. Prod.* **1990**, *53*, 995–999; (c) Stierle, D. B.; Faulkner, D. J. *J. Nat. Prod.* **1991**, *54*, 1134–1136; (d) Carroll, A. R.; Scheuer, P. J. *Tetrahedron* **1990**, *46*, 6637–6646; (e) Matsunaga, S.; Shinoda, K.; Fusetani, N. *Tetrahedron Lett.* **1993**, *34*, 5953–5954; (f) Wang, G.-Y.-S.; Kuramoto, M.; Uemura, D. *Tetrahedron Lett.* **1996**, *37*, 1813–1816.
3. (a) Schmitz, F. J.; Hollenbeak, K. H.; Campbell, D. C. *J. Org. Chem.* **1978**, *43*, 3913–3922; (b) Fusetani, N.; Yasumuro, K.; Matsunaga, S.; Hirota, H. *Tetrahedron Lett.* **1989**, *30*, 6891–6894; (c) Talpia, R.; Rudi, A.; Ilan, M.; Kashman, Y. *Tetrahedron Lett.* **1992**, *33*, 3033–3034; (d) Davies-Coleman, M. T.; Faulkner, D. J.; Dubowchik, G. M.; Roth, G. P.; Polson, C.; Fairchild, C. *J. Org. Chem.* **1993**, *58*, 5925–5930.
4. Kariya, Y.; Kubota, T.; Fromont, J.; Kobayashi, J. *Bioorg. Med. Chem.* **2006**, *14*, 8415–8419.
5. Kobayashi, J.; Murayama, T.; Ohizumi, Y.; Sasaki, T.; Ohta, T.; Nozoe, S. *Tetrahedron* **1989**, *30*, 4833–4836.
6. (a) Kobayashi, J.; Murayama, T.; Kosuge, S.; Kanda, F.; Ishibashi, M.; Kobayashi, H.; Ohizumi, Y.; Ohta, T.; Nozoe, S.; Sasaki, T. *J. Chem. Soc., Perkin Trans. 1* **1990**, 3301–3303; (b) Kobayashi, J.; Zeng, C.-M.; Ishibashi, M.; Shigemori, H.; Sasaki, T.; Mikami, Y. *J. Chem. Soc., Perkin Trans. 1* **1992**, 1291–1294.
7. (a) Tsuda, M.; Hirano, K.; Kubota, T.; Kobayashi, J. *Tetrahedron Lett.* **1999**, *40*, 4819–4820; (b) Hirano, K.; Kubota, T.; Tsuda, M.; Mikami, Y.; Kobayashi, J. *Chem. Pharm. Bull.* **2000**, *48*, 974–977; (c) Ishiyama, H.; Tsuda, M.; Endo, T.; Kobayashi, J. *Molecules* **2005**, *10*, 312–316.
8. Kariya, Y.; Kubota, T.; Fromont, J.; Kobayashi, J. *Tetrahedron Lett.* **2006**, *47*, 997–998.
9. *Nakinadine A* (**1**): A colorless oil; $[\alpha]_{\text{D}}^{23} -3$ (c 1.0, CHCl₃); UV (MeOH) λ_{max} 257 (ϵ 3700), 263 (4100), and 269 (3600) nm; IR (film) ν_{max} 3200 (br), 2850 (br), and 1725 cm⁻¹; ¹H NMR (CDCl₃) δ 8.44 (4H, m), 7.49 (2H, m), 7.32 (2H, m), 7.20 (2H, m), 7.19 (2H, m), 7.15 (m), 5.33 (2H, m), 3.75 (br s), 3.19 (br s), 2.75 (m), 2.62 (3H, m), 2.56 (2H, t, $J = 6.7$ Hz), 2.33 (2H, m), 1.89 (2H, m), 1.57 (2H, m), 1.54 (2H, m), 1.42 (2H, m), 1.43 (2H, m), 1.0–1.4 (34H, m); ¹³C NMR (CDCl₃) δ 176.0 (s), 149.6 (2C, d), 146.8 (2C, d), 136.9 (2C, s), 135.8 (s), 135.5 (2C, s), 131.1 (s), 129.4 (2C, s), 128.2 (2C, s), 127.4 (s), 127.0 (s), 122.9 (2C, d), 59.5 (s), 51.9 (s), 44.9 (s), 32.7 (2C, d), 30.8 (s), 28.5–30.0 (16C, m), 28.4 (s), 26.9 (2C, s), 26.6 (s); ESIMS (pos.) m/z 682 (M+H)⁺; HRESIMS m/z 682.5311 (M+H)⁺, $\Delta -0.0$ mmu.
10. Vysotskii, M. V.; Imbs, A. B.; Popkov, A. A.; Latyshev, N. A.; Svetachev, V. I. *Tetrahedron Lett.* **1990**, *31*, 4367–4370.
11. Matsumori, N.; Kaneno, D.; Murata, M.; Nakamura, H.; Tachibana, K. *J. Org. Chem.* **1999**, *64*, 866–876.
12. Christian, A. V.; Matthias, K. *Org. Biomol. Chem.* **2004**, *2*, 1827–1830.
13. Bieber, T. I.; Sites, R.; Chiang, Y. *J. Org. Chem.* **1958**, *23*, 300–301.